| Research Spending Per New Drug | ||||
| Company | Ticker | Number of drugs approved | R&D Spending Per Drug ($Mil) | Total R&D Spending 1997-2011 ($Mil) |
| AstraZeneca | AZN | 5 | 11,790.93 | 58,955 |
| GlaxoSmithKline | GSK | 10 | 8,170.81 | 81,708 |
| Sanofi | SNY | 8 | 7,909.26 | 63,274 |
| Roche Holding AG | RHHBY | 11 | 7,803.77 | 85,841 |
| Pfizer Inc. | PFE | 14 | 7,727.03 | 108,178 |
| Johnson & Johnson | JNJ | 15 | 5,885.65 | 88,285 |
| Eli Lilly & Co. | LLY | 11 | 4,577.04 | 50,347 |
| Abbott Laboratories | ABT | 8 | 4,496.21 | 35,970 |
| Merck & Co Inc | MRK | 16 | 4,209.99 | 67,360 |
| Bristol-Myers Squibb Co. | BMY | 11 | 4,152.26 | 45,675 |
| Novartis AG | NVS | 21 | 3,983.13 | 83,646 |
| Amgen Inc. | AMGN | 9 | 3,692.14 | 33,229 |
| Sources: InnoThink Center For Research In Biomedical Innovation; Thomson Reuters Fundamentals via FactSet Research Systems | ||||
A blog for humans in the universe, to understand what we know now and to imagine what we don't know. To bridge the gap between the real world, its image in our brain and the ideas generated by.
Aucun commentaire:
Enregistrer un commentaire